Claro (florfenicol/terbinafine/mometasone)

Claro is a combination otic solution manufactured by Elanco that contains three active ingredients: florfenicol (an antibiotic), terbinafine (an antifungal), and mometasone furoate (a corticosteroid). This medication is FDA-approved exclusively for the treatment of otitis externa in dogs and carries an explicit manufacturer warning stating that it should not be used in cats. The product labeling from both the FDA and Elanco clearly indicates "Do Not Use in Cats," making this one of the few veterinary ear medications with a specific contraindication for feline patients. Cat owners must understand that despite Claro's effectiveness in treating canine ear infections, this medication poses significant safety risks to cats and should never be administered to feline patients under any circumstances.

The mechanism of action in Claro involves three complementary therapeutic approaches working simultaneously to address ear infections. Florfenicol functions as a bacteriostatic antibiotic that inhibits bacterial protein synthesis, effectively preventing the reproduction of susceptible bacteria such as Staphylococcus pseudintermedius commonly found in ear infections. Terbinafine works as an antifungal agent by selectively inhibiting squalene epoxidase, an enzyme critical for ergosterol synthesis in fungal cell membranes, making it effective against Malassezia pachydermatis yeast. Mometasone furoate provides potent anti-inflammatory effects that reduce swelling, redness, and discomfort in the ear canal. While this triple-action approach works well in canine patients, cats metabolize these medications differently, and the combination has been associated with serious adverse reactions in feline patients.

Claro is uniquely formulated as a single-dose treatment designed to be administered exclusively by veterinary professionals in a clinical setting. The medication comes in a pre-measured dropperette that delivers exactly one milliliter of solution into each affected ear, and this single application is designed to provide therapeutic effects for up to thirty days. This veterinarian-administered approach eliminates the need for daily home treatment but also means cat owners would never have this medication at home to accidentally use on their feline pets. The extended-release formulation that makes Claro convenient for dog owners is part of what makes it potentially dangerous for cats, as the prolonged exposure to the active ingredients cannot be easily reversed once administered.

The importance of understanding Claro's contraindication in cats cannot be overstated for pet owners who have both dogs and cats in their household. If a veterinarian prescribes Claro for a canine family member, cat owners must ensure that their feline pets have no contact with the treated dog's ears and that any residual medication from head shaking does not contact cats. Post-approval adverse event reports submitted to the FDA have documented serious reactions in cats who received Claro through extra-label use, reinforcing why the manufacturer warning exists. Veterinary professionals have access to numerous safe and effective alternatives for treating feline ear infections, making there no justification for using Claro in cats when safer options are readily available.

Claro is FDA-approved solely for the treatment of otitis externa in dogs caused by susceptible strains of bacteria and yeast. The primary indication is for canine ear infections associated with Staphylococcus pseudintermedius bacteria and Malassezia pachydermatis yeast, which represent the most common pathogens found in dog ear infections. This medication is specifically designed for the canine ear canal anatomy and canine drug metabolism, and it has not been tested, approved, or deemed safe for use in cats. Cat owners searching for information about Claro should understand that this medication should never be used in feline patients, regardless of how similar the ear infection symptoms may appear to those in dogs.

The specific bacterial coverage of Claro centers on Staphylococcus pseudintermedius, which is the predominant bacterial pathogen isolated from canine otitis externa cases. This bacterium is part of the normal skin flora in dogs but can cause opportunistic infections when the ear environment becomes favorable for bacterial overgrowth. The florfenicol component of Claro has demonstrated effectiveness against this organism in clinical studies conducted exclusively in dogs. Cats have different bacterial flora in their ear canals, and the bacterial species causing feline otitis externa may differ significantly from those in dogs, further supporting why this canine-specific medication is inappropriate for cats.

The antifungal indication for Claro targets Malassezia pachydermatis, a lipophilic yeast that commonly colonizes the ear canals of dogs and can proliferate during otitis externa. While Malassezia species can also affect cats, the terbinafine component of Claro and its extended-release formulation have only been evaluated for safety and efficacy in canine patients. Cats with yeast-related ear infections have numerous other treatment options that have been evaluated for feline safety, making the use of Claro in cats both unnecessary and potentially dangerous. The antifungal activity, while beneficial in dogs, does not justify the risks associated with feline exposure to this medication.

Claro has no approved or legitimate off-label uses in cats, and veterinary dermatologists strongly advise against its use in feline patients based on reported adverse events. Unlike many veterinary medications that are safely used across species with appropriate dose adjustments, Claro has demonstrated a pattern of serious adverse reactions specific to cats that precludes any off-label consideration. The FDA's adverse event reporting database contains documented cases of cats experiencing vestibular dysfunction, Horner's syndrome, ataxia, and other neurological signs following Claro administration. These reports have reinforced the manufacturer's original contraindication and serve as a warning to veterinary professionals and pet owners alike.

When cat owners observe signs of ear infection in their feline pets, such as head shaking, ear scratching, discharge, or odor, they should seek veterinary care for proper diagnosis and treatment with cat-safe medications. Feline otitis externa can have different underlying causes than canine ear infections, including ear mites, polyps, allergies, and various bacterial or fungal pathogens. A veterinarian can perform appropriate diagnostics including otoscopic examination, cytology, and culture when needed to determine the specific cause and prescribe an appropriate feline-safe treatment. Numerous effective ear medications exist that are either FDA-approved for cats or have established safety profiles for off-label feline use, making Claro completely unnecessary for treating cat ear problems.

Claro should never be administered to cats under any circumstances, and therefore no feline dosing information exists or should be sought. The following dosage information pertains exclusively to the approved canine use and is provided solely for educational purposes to help cat owners understand why this medication format is inappropriate for feline patients. In dogs, Claro is administered as a single one-milliliter dose into each affected ear canal, and this single application is designed to provide therapeutic concentrations for approximately thirty days. The extended-release formulation and single-dose protocol that works well in dogs represents a significant safety concern if mistakenly used in cats, as the prolonged drug exposure cannot be reversed.

The administration of Claro in dogs must be performed exclusively by veterinary professionals in a clinical setting, which provides an important safeguard against accidental feline exposure at home. Veterinarians verify tympanic membrane integrity before administration, as the medication should not be used in patients with ruptured eardrums. The dropperette delivery system ensures precise dosing, and veterinary staff are trained in proper administration technique including gentle massage of the ear base to distribute the medication throughout the ear canal. Cat owners should be reassured that they will never be sent home with Claro to administer themselves, reducing the risk of accidental administration to household cats.

The treatment duration for Claro in dogs is unique among otic medications because a single veterinary-administered dose replaces the typical seven to fourteen day course of daily home treatments required by most ear medications. This extended-release technology relies on the medication adhering to the ear canal tissues and slowly releasing active ingredients over time. In cats, this prolonged exposure is precisely what makes the medication dangerous, as adverse reactions may develop gradually and cannot be stopped by simply discontinuing daily treatments as would be possible with conventional ear drops. If a cat were accidentally exposed to Claro, the extended-release nature would complicate management of any adverse reactions.

There are no circumstances under which a cat owner should attempt to obtain or administer Claro to a feline patient, even if they believe their cat has a similar ear condition to a dog previously treated with this medication. The convenience of single-dose treatment that appeals to dog owners does not outweigh the serious safety risks in cats. If a veterinarian ever suggests using Claro in a cat, the owner should question this recommendation and ask about the FDA contraindication, as this would represent a significant deviation from established safety guidelines. Veterinary professionals are trained to know this contraindication, but errors can occur, and informed pet owners serve as an important safety check.

For cats with ear infections, numerous alternative medications exist that require daily home administration but offer established safety profiles in feline patients. Products such as Tresaderm, Mometamax, and Surolan have been used extensively in cats with acceptable safety records, even if some are technically off-label. While these alternatives require more owner involvement in treatment, this daily administration actually provides benefits including the ability to monitor treatment response, discontinue therapy if problems arise, and adjust treatment duration based on clinical improvement. Cat owners should embrace these proven feline-appropriate options rather than seeking the single-dose convenience of a medication that poses documented risks to their pets.

If accidental exposure of a cat to Claro occurs, whether through direct administration or contact with a treated dog's ears, immediate veterinary consultation is essential. The veterinarian may recommend ear flushing to remove as much medication as possible, though the extended-release formulation may limit the effectiveness of this intervention. Monitoring for signs of vestibular dysfunction, neurological changes, and other adverse effects should continue for several weeks following exposure. Documentation of the exposure and any subsequent adverse events through the FDA's adverse event reporting system helps build the safety database that protects other cats from similar incidents.

Claro has demonstrated a significant adverse reaction profile in cats that forms the basis for its contraindication in feline patients. The FDA's post-approval adverse event reporting database contains numerous documented cases of cats experiencing serious reactions following Claro administration, and these reports led to strengthened label warnings. Unlike typical side effects that may occur in any species, the reactions documented in cats represent a pattern of serious, sometimes irreversible, neurological and systemic effects that clearly indicate this medication is not safe for feline use. Cat owners must understand these documented feline-specific adverse reactions to appreciate why Claro carries such a strong warning against use in cats.

The most frequently reported adverse reactions in cats exposed to Claro involve vestibular dysfunction and associated neurological signs. Cats have experienced ataxia (loss of coordination and balance), head tilt, nystagmus (abnormal repetitive eye movements), and general incoordination following Claro administration. These vestibular signs indicate effects on the inner ear and associated neurological pathways that appear to be more pronounced in cats than in dogs. In some cases, these vestibular effects have been severe enough to significantly impact the cat's quality of life and ability to perform normal activities. While some affected cats have shown improvement over time, others have experienced prolonged or permanent vestibular dysfunction.

Horner's syndrome has been reported in cats following Claro administration, representing another serious neurological adverse effect. This condition involves dysfunction of the sympathetic nerve supply to the eye and face, resulting in a characteristic set of signs including third eyelid prolapse (protrusion of the nictitating membrane), miosis (constricted pupil), ptosis (drooping eyelid), and enophthalmos (sunken eye appearance). Horner's syndrome in cats following Claro exposure suggests the medication or its components may affect neural structures in ways that differ significantly from the canine response. The appearance of Horner's syndrome in a cat should prompt immediate veterinary evaluation and, if Claro exposure has occurred, should be reported as an adverse event.

Deafness and hearing impairment have been documented in cats exposed to Claro, representing one of the most concerning potential outcomes. Ototoxicity, or damage to the structures of the ear responsible for hearing and balance, appears to be a risk in feline patients exposed to this medication. While some cases of hearing loss may be temporary and resolve over time, permanent deafness has been reported. The extended-release formulation of Claro means that once administered, the ear cannot be simply flushed to remove the medication, potentially prolonging exposure of sensitive inner ear structures to ototoxic effects. Cats are highly dependent on their hearing for environmental awareness and communication, making drug-induced deafness a particularly devastating outcome.

Additional adverse reactions reported in cats include anorexia (loss of appetite), lethargy, vomiting, and general malaise following Claro exposure. Some cats have experienced anisocoria (unequal pupil sizes), which may indicate neurological effects or be associated with the Horner's syndrome cases. Tympanic membrane rupture has been reported, which could either be a pre-existing condition that allowed deeper penetration of the medication or a direct effect of the drug on the eardrum tissue. The combination and severity of these adverse reactions in cats clearly demonstrates that this medication affects feline patients differently than dogs, supporting the manufacturer's explicit contraindication. Any cat owner whose pet has been accidentally exposed to Claro should monitor closely for any of these signs and seek immediate veterinary care if they develop.

The primary and most critical contraindication for Claro is its use in cats, which is explicitly stated on all product labeling with the clear directive "Do Not Use in Cats." This contraindication is absolute and not subject to clinical judgment or dose modification, as the medication has demonstrated a pattern of serious adverse reactions in feline patients that cannot be mitigated through careful use. Unlike relative contraindications that may be overridden in certain clinical circumstances, the feline contraindication for Claro represents a fundamental incompatibility between this medication and cat physiology. Veterinary professionals and pet owners must respect this contraindication without exception.

Beyond the categorical feline contraindication, Claro is contraindicated in any patient with known hypersensitivity to florfenicol, terbinafine hydrochloride, or mometasone furoate. Dogs with documented allergic reactions to any of these active ingredients or related compounds should not receive Claro. Similarly, if a dog has previously experienced an adverse reaction to Claro specifically, the medication should not be re-administered. While these hypersensitivity contraindications apply to dogs (the only approved species), they serve as a reminder that individual patients may have unpredictable reactions to medication components.

Claro is contraindicated in dogs with known or suspected tympanic membrane perforation, and this contraindication would theoretically apply to any species if the drug were being considered. The integrity of the eardrum must be verified by veterinary examination before Claro administration, as the medication could potentially cause serious harm if it enters the middle or inner ear through a ruptured tympanic membrane. This requirement for pre-administration otoscopic examination is one reason why Claro must be administered by veterinary professionals rather than dispensed for home use. In cats, this safeguard is irrelevant because the medication should never be used in feline patients regardless of eardrum status.

The safe use of Claro has not been evaluated in dogs used for breeding purposes, during pregnancy, or in lactating females, representing additional populations where the medication is not recommended even in the approved canine species. These reproductive safety limitations further narrow the appropriate patient population and remind pet owners that even FDA-approved medications have use restrictions. For cats, these reproductive warnings are superseded by the complete species contraindication, but they illustrate how medication safety involves multiple considerations beyond simply species approval. Cat owners should understand that there is no scenario, reproductive or otherwise, where Claro use in cats would be appropriate.

While drug interaction information for Claro pertains to its approved use in dogs, understanding these interactions provides educational context for cat owners about why combining medications requires veterinary guidance. The most important interaction consideration for cat owners is ensuring that any ear medications prescribed for their feline pets are specifically appropriate for cats and do not interact adversely with other medications their cat may be receiving. Since Claro itself should never be used in cats, the relevant drug interaction considerations involve the cat-safe alternatives that veterinarians may prescribe for feline ear infections.

In dogs, Claro should not be used concurrently with other otic preparations unless specifically directed by a veterinarian. The extended-release formulation is designed to work independently over a thirty-day period, and adding other ear medications could potentially interfere with drug release, alter efficacy, or increase the risk of adverse reactions. This principle of avoiding concurrent otic therapy applies broadly to ear medications in all species, including cats. When cats are prescribed ear medications, owners should not supplement with over-the-counter ear products, leftover medications from previous infections, or remedies obtained without veterinary guidance.

The mometasone furoate component of Claro is a corticosteroid that can be absorbed systemically and may interact with other medications or affect certain medical conditions. In dogs receiving systemic corticosteroids, addition of topical otic corticosteroids could potentially contribute to cumulative corticosteroid effects. Cats are generally more sensitive to corticosteroid effects than dogs, which is one potential factor in why Claro causes problems in feline patients. Cat owners whose pets are receiving any form of corticosteroid therapy should inform their veterinarian so appropriate ear medication choices can be made that account for total corticosteroid exposure.

The florfenicol antibiotic component of Claro belongs to the amphenicol class of antibiotics, which have specific interaction considerations in some species. While topical otic administration limits systemic exposure compared to oral or injectable routes, veterinarians consider the complete medication profile when prescribing treatments. Cats have different antibiotic metabolism and sensitivity profiles compared to dogs, which may contribute to the adverse reaction pattern observed with Claro in feline patients. Cat owners should always provide their veterinarian with a complete list of all medications, supplements, and treatments their cat receives to enable safe prescribing decisions.

The paramount precaution for Claro is the absolute contraindication for use in cats, which warrants repeated emphasis given the serious consequences of feline exposure. Cat owners in households that also include dogs should be particularly vigilant if a canine family member receives Claro treatment. While the medication is administered by veterinary staff rather than sent home, treated dogs may shake their heads following application, potentially splattering medication residue onto nearby surfaces, people, or other pets. Cats should be kept separate from recently treated dogs until any potential for medication transfer has passed, and any visible residue should be cleaned promptly.

Veterinary professionals should exercise extreme caution to ensure Claro is never inadvertently dispensed or administered to feline patients. While the product labeling clearly states the feline contraindication, busy clinical environments can sometimes lead to errors if staff are not consistently vigilant. Veterinary practices should consider implementing specific safeguards such as clear labeling systems, storage separation from feline-approved products, and verification protocols before administration. Client communication should emphasize the species-specific nature of this medication to pet owners with multiple species in their households.

For dog owners, important precautions include the requirement for veterinary examination to verify tympanic membrane integrity before Claro administration. The medication should only be used in dogs with intact eardrums, as penetration into the middle ear could cause serious complications. Dogs receiving Claro should be monitored for any signs of ear pain, hearing changes, vestibular dysfunction, or worsening symptoms, and owners should report any concerns to their veterinarian promptly. While adverse reactions in dogs are less common than in cats, they can still occur and warrant attention.

Human precautions are also important when handling Claro or caring for recently treated dogs. The product contains corticosteroid and other active ingredients that can affect humans with sensitivities to these compounds. Pregnant women should use caution when handling the medication or touching treated dogs' ears, as corticosteroids may pose risks during pregnancy. Anyone who experiences accidental skin contact should wash the affected area immediately with soap and water, and accidental eye exposure requires thorough flushing with water for at least fifteen minutes followed by medical consultation if irritation persists. These human safety precautions apply regardless of whether the household includes cats.

Owners of cats who suspect their pet may have been accidentally exposed to Claro, whether through direct application by someone unaware of the contraindication or through contact with a treated dog, should seek veterinary care immediately. Early intervention may help mitigate adverse effects, though the extended-release formulation limits treatment options once exposure has occurred. Documentation of the exposure circumstances and timing helps veterinary professionals provide appropriate monitoring and care. Reporting suspected adverse events to the FDA through their Safety Reporting Portal contributes to the ongoing surveillance that helps protect other pets from similar incidents.

Claro should be stored at controlled room temperature between sixty-eight and seventy-seven degrees Fahrenheit, with brief temperature excursions permitted between fifty-nine and eighty-six degrees Fahrenheit as may occur during normal handling and transport. The medication should be protected from excessive heat and should not be frozen. Proper storage maintains the stability and efficacy of the extended-release formulation throughout its shelf life. While these storage requirements are standard for many veterinary medications, they are primarily relevant to veterinary practices that stock Claro rather than pet owners, since this medication is administered in-clinic rather than dispensed for home use.

The single-dose dropperette packaging of Claro has specific handling requirements that veterinary staff must follow for proper administration. The dropperette should be shaken well before use to ensure uniform suspension of the active ingredients. The cap must be removed and reversed to break the seal on the tip, then an applicator nozzle is attached for ear canal insertion. The entire contents of one dropperette (one milliliter) are instilled into each affected ear, and the used dropperette should be disposed of appropriately. This single-use packaging eliminates concerns about medication degradation after opening that exist with multi-dose bottles.

In households with both dogs and cats, any Claro-related materials should be kept completely away from cats and disposed of properly. While pet owners do not typically have Claro in their homes due to the veterinarian-administered protocol, any informational materials, packaging, or promotional items related to the product should not lead cat owners to believe this medication is an option for their feline pets. Veterinary practices disposing of unused or expired Claro should follow appropriate pharmaceutical waste disposal guidelines and ensure the product cannot be accessed by animals or used inappropriately.

Proper handling of Claro by veterinary staff includes wearing appropriate eye protection during administration, as head shaking by dogs following application can cause medication splatter that may result in eye exposure. Staff should wash hands thoroughly after handling the product and before interacting with feline patients to prevent any potential cross-contamination. These handling precautions protect both human staff and feline patients in veterinary facilities where multiple species are treated throughout the day.

Breed considerations for Claro are relevant only within the context of its approved canine use, as no cat breed should ever receive this medication due to the categorical species contraindication. The "Do Not Use in Cats" warning applies universally to all feline breeds, sizes, and ages without exception. Whether an owner has a robust Maine Coon, a delicate Siamese, a hairless Sphynx, or a common domestic shorthair, Claro is equally contraindicated across all feline genetic backgrounds. There is no cat breed with unique physiology that would make Claro safe or appropriate, and owners should not assume that any breed-specific characteristic might reduce the risks associated with this medication.

Some cat breeds may have anatomical ear characteristics that make them more prone to ear infections, potentially leading owners to seek aggressive treatment options. Breeds such as the Scottish Fold, with their distinctive folded ear cartilage, or Persian cats with their facial conformation, may experience ear problems more frequently than other breeds. However, increased susceptibility to ear infections does not change the contraindication status of Claro. Veterinarians have access to numerous cat-safe alternatives that can effectively treat ear infections in all breeds, including those with challenging ear anatomy or chronic otitis tendencies.

In dogs, where Claro is approved, certain breed considerations may apply to its use. Some dog breeds are predisposed to ear infections due to ear anatomy, skin conditions, or allergies, and Claro may be selected for these patients due to its convenience and broad-spectrum coverage. German Shepherds, Cocker Spaniels, Basset Hounds, and other breeds with pendulous ears or high rates of allergic skin disease commonly present for otitis externa treatment. However, these canine breed considerations have no relevance to feline patients, and cat owners should not extrapolate from their dog's successful Claro treatment to consider it for household cats.

Age considerations in cats similarly do not modify the Claro contraindication. Kittens, adult cats, and senior cats are all equally at risk for adverse reactions from Claro exposure. In fact, very young and very old cats may have reduced metabolic capacity that could potentially worsen adverse reactions, though this is speculative since appropriate safety studies have never been conducted in cats and never should be given the known risks. Cat owners should ensure that any cat of any age is protected from Claro exposure by understanding the contraindication and communicating with veterinary staff about their multi-pet household status.

For cat owners seeking appropriate alternatives to treat feline ear infections, several combination otic medications have established safety profiles for use in cats. Tresaderm (thiabendazole, dexamethasone, and neomycin) is FDA-approved for use in both dogs and cats and represents a time-tested option for feline otitis externa. Mometamax (gentamicin, mometasone, and clotrimazole) is commonly used off-label in cats for ear infections, particularly those involving Pseudomonas bacteria, with generally acceptable safety when used appropriately. Surolan (miconazole, polymyxin B, and prednisolone) is approved for cats in some regions and used off-label in others, offering another combination option for feline ear infections.

Other cat-appropriate otic options include single-agent preparations and different combination formulations depending on the specific pathogens identified on ear cytology. Posatex (orbifloxacin, posaconazole, and mometasone) is used off-label in cats and may be preferred when Pseudomonas infection is suspected due to its fluoroquinolone antibiotic component. Otomax (gentamicin, betamethasone, and clotrimazole) has been used in cats though it requires twice-daily application compared to Mometamax's once-daily dosing. These alternatives allow veterinarians to select appropriate therapy based on the specific infection type, patient factors, and owner compliance capabilities.

For cat owners whose dogs have been successfully treated with Claro, it is important to understand that the convenience of single-dose veterinary-administered treatment is not available for their feline pets. Cat ear medications require more owner involvement through daily or twice-daily home application, but this additional effort ensures the safety of feline patients. The daily administration also provides advantages including the ability to monitor response to treatment, adjust therapy duration based on improvement, and discontinue medication immediately if any adverse effects are observed. Cat owners should embrace these proven alternatives rather than seeking the convenience of a medication that poses documented risks to cats.

Veterinary consultation is essential for selecting the most appropriate ear medication for any cat with suspected otitis externa. Different underlying causes including bacterial infection, yeast overgrowth, ear mites, allergies, or polyps require different treatment approaches. Ear cytology performed by the veterinarian helps identify the specific pathogens present and guides medication selection. Cat owners should never attempt to treat ear infections with leftover medications from other pets, over-the-counter preparations, or home remedies, as inappropriate treatment can worsen infections, cause injury, and delay effective therapy. The relationship with a trusted veterinarian ensures cats receive safe, effective treatment tailored to their specific condition.